Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Publishing confirming and non-confirming data.

Alberts B, Kamb A.

F1000Res. 2016 Feb 4;5:135. doi: 10.12688/f1000research.7847.1. eCollection 2016.

2.

SCIENTIFIC INTEGRITY. Self-correction in science at work.

Alberts B, Cicerone RJ, Fienberg SE, Kamb A, McNutt M, Nerem RM, Schekman R, Shiffrin R, Stodden V, Suresh S, Zuber MT, Pope BK, Jamieson KH.

Science. 2015 Jun 26;348(6242):1420-2. doi: 10.1126/science.aab3847. No abstract available.

3.

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.

Li C, Liu L, Liang L, Xia Z, Li Z, Wang X, McGee LR, Newhall K, Sinclair A, Kamb A, Wickramasinghe D, Dai K.

Mol Cancer Ther. 2015 Feb;14(2):375-83. doi: 10.1158/1535-7163.MCT-14-0388. Epub 2014 Dec 8.

4.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

Li Z, Wang X, Eksterowicz J, Gribble MW Jr, Alba GQ, Ayres M, Carlson TJ, Chen A, Chen X, Cho R, Connors RV, DeGraffenreid M, Deignan JT, Duquette J, Fan P, Fisher B, Fu J, Huard JN, Kaizerman J, Keegan KS, Li C, Li K, Li Y, Liang L, Liu W, Lively SE, Lo MC, Ma J, McMinn DL, Mihalic JT, Modi K, Ngo R, Pattabiraman K, Piper DE, Queva C, Ragains ML, Suchomel J, Thibault S, Walker N, Wang X, Wang Z, Wanska M, Wehn PM, Weidner MF, Zhang AJ, Zhao X, Kamb A, Wickramasinghe D, Dai K, McGee LR, Medina JC.

J Med Chem. 2014 Apr 24;57(8):3430-49. doi: 10.1021/jm500118j. Epub 2014 Apr 2.

PMID:
24641103
5.

Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.

Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, Hollenback D, Eksterowicz J, Liang L, Weidner M, Huard J, Wang X, Alba G, Orf J, Lo MC, Zhao S, Ngo R, Chen A, Liu L, Carlson T, Quéva C, McGee LR, Medina J, Kamb A, Wickramasinghe D, Dai K.

Mol Cancer Ther. 2014 Apr;13(4):880-9. doi: 10.1158/1535-7163.MCT-13-0858. Epub 2014 Feb 13.

6.

Human genetics as a foundation for innovative drug development.

Kamb A, Harper S, Stefansson K.

Nat Biotechnol. 2013 Nov;31(11):975-8. doi: 10.1038/nbt.2732. No abstract available.

PMID:
24213769
7.

Sphingosine kinase activity is not required for tumor cell viability.

Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, Schmidt J, Swearingen E, Walker N, Wang Z, Watson JE, Wickramasinghe D, Wong M, Xu G, Wesche H.

PLoS One. 2013 Jul 5;8(7):e68328. doi: 10.1371/journal.pone.0068328. Print 2013.

8.

Next-generation sequencing and its potential impact.

Kamb A.

Chem Res Toxicol. 2011 Aug 15;24(8):1163-8. doi: 10.1021/tx200121m. Epub 2011 Jun 10. Review.

PMID:
21630708
9.

Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways.

Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL.

PLoS One. 2010 Sep 30;5(9). pii: e13024. doi: 10.1371/journal.pone.0013024.

10.

At a crossroads in oncology.

Kamb A.

Curr Opin Pharmacol. 2010 Aug;10(4):356-61. doi: 10.1016/j.coph.2010.05.006. Epub 2010 Jun 9.

PMID:
20542731
11.

Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer.

Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL.

PLoS One. 2009 May 29;4(5):e5722. doi: 10.1371/journal.pone.0005722.

12.

Why is cancer drug discovery so difficult?

Kamb A, Wee S, Lengauer C.

Nat Rev Drug Discov. 2007 Feb;6(2):115-20. doi: 10.1038/nrd2155. Epub 2006 Dec 8. Review.

PMID:
17159925
13.

What's wrong with our cancer models?

Kamb A.

Nat Rev Drug Discov. 2005 Feb;4(2):161-5. Review.

PMID:
15688078
14.

Non-traditional drug targets: high risk, high reward.

Sandrock T, Kamb A.

Curr Gene Ther. 2003 Oct;3(5):395-404. Review.

PMID:
14529347
15.

Isolation of a peptide inhibitor of human rhinovirus.

Poritz MA, Malmstrom S, Schmitt A, Kim MK, Zharkikh L, Kamb A, Teng DH.

Virology. 2003 Aug 15;313(1):170-83.

16.

Overexpression of the beta-catenin binding domain of cadherin selectively kills colorectal cancer cells.

Pierce M, Wang C, Stump M, Kamb A.

Int J Cancer. 2003 Nov 1;107(2):229-37.

17.

Functional analysis of expressed peptides that bind yeast STE proteins.

Caponigro G, Abedi M, Kamb A.

J Biotechnol. 2003 Aug 15;103(3):213-25.

PMID:
12890608
18.

A high-throughput, homogeneous microplate assay for agents that kill mammalian tissue culture cells.

Pierce M, Wang C, Rebentisch M, Endo M, Stump M, Kamb A.

J Biomol Screen. 2003 Jun;8(3):283-91.

PMID:
12857382
19.
20.

Consequences of nonadaptive alterations in cancer.

Kamb A.

Mol Biol Cell. 2003 Jun;14(6):2201-5. Epub 2003 Feb 21. No abstract available.

21.

A genetic selection method for expression products that induce apoptosis in adherent mammalian cell lines.

Sandrock R, Wheatley W, Drees E, Lualhati M, Kamb A, Caponigro G.

Apoptosis. 2003 Mar;8(2):209-19.

PMID:
12766481
22.

Genetic selection for modulators of a retinoic-acid-responsive reporter in human cells.

Richards B, Karpilow J, Dunn C, Peterson I, Maxfield A, Zharkikh L, Abedi M, Hurlburt A, Hardman J, Hsu F, Li W, Rebentisch M, Sandrock R, Sandrock T, Kamb A, Teng DH.

Genetics. 2003 Mar;163(3):1047-60.

23.

Universities could gain from backing biotech.

Kamb A.

Nature. 2003 Mar 13;422(6928):113. No abstract available.

PMID:
12634753
24.

Genetic selection for modulators of the MAP kinase and beta-catenin growth-control pathways in mammalian cells.

Wheatley W, Yoo S, Pierce M, Rebentisch M, Endo M, Peterson I, Stump M, McCormack K, Garcia-Guzman M, Kamb A.

Biochem Genet. 2002 Dec;40(11-12):359-78.

PMID:
12463345
25.

Stable expression of Anthozoa fluorescent proteins in mammalian cells.

Richards B, Zharkikh L, Hsu F, Dunn C, Kamb A, Teng DH.

Cytometry. 2002 Jun 1;48(2):106-12.

26.

An automated system for screening retroviral expression constructs in microplate format.

Stump MD, Di Sera L, Rebentisch M, Endo M, Pierce M, Kamb A.

J Biomol Screen. 2002 Jun;7(3):275-80.

PMID:
12097190
27.

Enhanced expression of exogenous genes from retroviruses using HIV2/Tat.

Sandrock RW, Peterson I, Evans C, Wheatley W, Kamb A.

J Biotechnol. 2002 Jul 17;97(1):41-50.

PMID:
12052681
28.

Expression levels of transdominant peptides and proteins in Saccharomyces cerevisiae.

Sandrock T, Poritz M, Kim M, Feldhaus MJ, Roth B, Caponigro G, Kamb A.

Yeast. 2002 Jan 15;19(1):1-7.

29.

Exogenous peptide and protein expression levels using retroviral vectors in human cells.

Sandrock TM, Risley B, Richards BT, Poritz MA, Austin HA, Yoo S, Kim MK, Roth B, Repetny K, Hsu F, Stump M, Teng DH, Kamb A.

Mol Ther. 2001 Nov;4(5):398-406.

30.
31.

Enrichment during transdominant genetic experiments using a flow sorter.

Sandrock R, Karpilow J, Richards B, Maxfield A, Wang C, Risley R, Rebentisch M, Drees B, Teng DH, Caponigro G, Kamb A.

Cytometry. 2001 Oct 1;45(2):87-95.

PMID:
11590620
32.

Creation of a stable human reporter cell line suitable for FACS-based, transdominant genetic selection.

Richards B, Karpilow J, Dunn C, Zharkikh L, Maxfield A, Kamb A, Teng DH.

Somat Cell Mol Genet. 1999 Jul;25(4):191-205.

PMID:
11586787
33.

Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins.

Abedi M, Caponigro G, Shen J, Hansen S, Sandrock T, Kamb A.

BMC Mol Biol. 2001;2:10. Epub 2001 Aug 31.

34.

Graded mode of transcriptional induction in yeast pheromone signalling revealed by single-cell analysis.

Poritz MA, Malmstrom S, Kim MK, Rossmeissl PJ, Kamb A.

Yeast. 2001 Oct;18(14):1331-8.

35.

Template selection during manipulation of complex mixtures by PCR.

Teng DH, Hsu F, Peterson I, Cardon KE, Caponigro G, Kamb A.

Biotechniques. 2001 Apr;30(4):868-72, 874, 876-7.

36.

Transdominant genetics, peptide inhibitors and drug targets.

Kamb A, Teng DH.

Curr Opin Mol Ther. 2000 Dec;2(6):662-9. Review.

PMID:
11249744
37.

Peptide inhibitors expressed in vivo.

Kamb A, Caponigro G.

Curr Opin Chem Biol. 2001 Feb;5(1):74-7. Review.

PMID:
11166652
38.

Oligonucleotide-conjugated beads for transdominant genetic experiments.

Feldhaus MJ, Lualhati M, Cardon K, Roth B, Kamb A.

Nucleic Acids Res. 2000 Jan 15;28(2):534-43.

39.

Transdominant genetic analysis of a growth control pathway.

Caponigro G, Abedi MR, Hurlburt AP, Maxfield A, Judd W, Kamb A.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7508-13.

40.

Cyclin-dependent kinase inhibitors and human cancer.

Kamb A.

Curr Top Microbiol Immunol. 1998;227:139-48. Review. No abstract available.

PMID:
9479829
41.

Green fluorescent protein as a scaffold for intracellular presentation of peptides.

Abedi MR, Caponigro G, Kamb A.

Nucleic Acids Res. 1998 Jan 15;26(2):623-30.

42.

A review of inherited predisposition to melanoma.

Cannon-Albright LA, Kamb A, Skolnick M.

Semin Oncol. 1996 Dec;23(6):667-72. Review.

PMID:
8970585
43.

Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.

Stone S, Dayananth P, Kamb A.

Cancer Res. 1996 Jul 15;56(14):3199-202.

44.

Low incidence of BRCA2 mutations in breast carcinoma and other cancers.

Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK, Kamb A.

Nat Genet. 1996 Jun;13(2):241-4.

PMID:
8640236
45.

The cancers of man and woman.

Kamb A, Neuhausen S.

Trends Genet. 1996 May;12(5):198. No abstract available.

PMID:
8984736
46.

Human melanoma genetics.

Kamb A.

J Investig Dermatol Symp Proc. 1996 Apr;1(2):177-82. Review.

PMID:
9627713
47.

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.

Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AK, Shizuya H, Eyfjord JE, Cannon-Albright L, Tranchant M, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE.

Nat Genet. 1996 Mar;12(3):333-7.

PMID:
8589730
48.

Identification of the BRCA1 breast cancer gene and its clinical implications.

Kamb A, Skolnick MH.

Important Adv Oncol. 1996:23-35. Review. No abstract available.

PMID:
8791126
49.

Monitoring the efficacy of hybrid selection during positional cloning: the search for BRCA1.

Hattier T, Bell R, Shaffer D, Stone S, Phelps RS, Tavtigian SV, Skolnick MH, Shattuck-Eidens D, Kamb A.

Mamm Genome. 1995 Dec;6(12):873-9.

PMID:
8747927
50.

Efficient, automatic detection of heterozygous bases during large-scale DNA sequence screening.

Phelps RS, Chadwick RB, Conrad MP, Kronick MN, Kamb A.

Biotechniques. 1995 Dec;19(6):984-9.

PMID:
8747666

Supplemental Content

Support Center